Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

311
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
311
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

321
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
321
Tumor Immunotherapy01:27

Tumor Immunotherapy

955
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
955
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

338
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
338
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

846
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
846
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

307
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
307

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Toxoplasmosis meets the World Health Organization criteria for a neglected tropical disease.

PLoS neglected tropical diseases·2026
Same author

Bilateral Giant Pigment Epithelial Detachments and Unilateral RPE Tear and Exudative Retinal Detachment After Tadalafil Exposure: Case Report and Review of the Literature.

Retinal cases & brief reports·2026
Same author

Treat-to-target in Behçet syndrome.

Nature reviews. Rheumatology·2026
Same author

Clonal haematopoiesis of indeterminate potential and relapses in patients with GCA.

Rheumatology (Oxford, England)·2026
Same author

Characteristics of Uveitis in European Tertiary Ophthalmology Centers: A Systematic Review and Meta-Analysis.

Ocular immunology and inflammation·2026
Same author

EULAR recommendations for the management of Behçet's syndrome: 2025 update.

Annals of the rheumatic diseases·2026
Same journal

Evidence-Based Clinical Recommendations for the Appropriate Use of Diagnostic Tests in Pediatric Allergology: Focus on Asthma, Rhinoconjunctivitis, and Keratoconjunctivitis Vernal.

Journal of clinical medicine·2026
Same journal

Surgical and Transcatheter Approach of a Failed Mitral Valve Repair: A Comprehensive Review on Selecting the Most Suitable Approach.

Journal of clinical medicine·2026
Same journal

Hybrid Metaheuristic Feature Selection for Breast Cancer Detection in Digital Mammography: A Feasibility Study with Nested Validation, Benchmarking, and External Stress Testing.

Journal of clinical medicine·2026
Same journal

Identity Transformation and the Role of Accountability in Recovery from Problematic Pornography Use: A Phenomenological-Hermeneutical Study.

Journal of clinical medicine·2026
Same journal

Does Early Surgical Treatment in Degenerative Cervical Myelopathy Have a Favorable Clinical Outcome and Impact on Quality of Life?

Journal of clinical medicine·2026
Same journal

Shear Wave Elastography in Musculoskeletal Imaging: A Narrative Review.

Journal of clinical medicine·2026
See all related articles

Related Experiment Video

Updated: Dec 1, 2025

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

5.6K

Biotherapies in Uveitis.

Mathilde Leclercq1,2, Anne-Claire Desbois2,3,4, Fanny Domont2,3,4

  • 1Department of Internal Medicine, Hôpital Charles Nicolle, F-76000 Rouen, France.

Journal of Clinical Medicine
|November 11, 2020
PubMed
Summary
This summary is machine-generated.

Non-infectious uveitis (NIU) is a leading cause of blindness. This review updates knowledge on biological treatments, particularly anti-tumor necrosis factor alpha (anti-TNF-α) agents, for managing NIU effectively.

Keywords:
Janus Associated Kinase (JAK) inhibitorsanti-TNF-α (anti-tumor necrosis factor alpha) agentbiotherapynon-infectious uveitistocilizumab

More Related Videos

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

3.0K
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

615

Related Experiment Videos

Last Updated: Dec 1, 2025

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

5.6K
Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

3.0K
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

615

Area of Science:

  • Ophthalmology
  • Immunology

Background:

  • Non-infectious uveitis (NIU) is a primary cause of vision loss in developed nations.
  • Current therapeutic strategies focus on controlling inflammation, preventing ocular damage, and reducing corticosteroid dependence.

Purpose of the Study:

  • To provide an updated overview of biological treatments for non-infectious uveitis.
  • To address current challenges and unanswered questions regarding the use of biologics in NIU management.

Main Methods:

  • Review of current literature on biological therapies for NIU.
  • Focus on anti-tumor necrosis factor alpha (anti-TNF-α) agents, including adalimumab (ADA) and infliximab (IFX).

Main Results:

  • Systemic treatment, including biotherapies, is crucial for intermediate, posterior, and pan-uveitis.
  • Anti-TNF-α agents are the most common biologics used, with specific indications for IFX and ADA in certain conditions like Behçet's disease.
  • Key questions remain regarding treatment duration, discontinuation protocols, and alternative biologic selection after anti-TNF-α failure.

Conclusions:

  • Biotherapies, especially anti-TNF-α agents, are integral to managing sight-threatening non-infectious uveitis.
  • Further research is needed to optimize long-term management strategies and address treatment gaps for NIU.